Changes in hemostatic parameters after oral hormone therapy in postmenopausal women

Journal of Women's Health

Volumn 19, Issue 12, 2010, Pages 2267-2270

  Borowiecka, Marta ^a   Polac, Ireneusz ^b   Nowak, Pawel ^a   Radwan, Pawel ^c   Ponczek, Michal B ^a   Wachowicz, Barbara ^a  

^a UNIVERSITY OF LODZ   (Poland)

^b POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

^c Fertility Center Gameta   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

DYDROGESTERONE; ESTRADIOL; FIBRIN; FIBRINOGEN;

ADULT; ARTICLE; BLOOD CLOT LYSIS; BLOOD CLOTTING; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HORMONAL THERAPY; HUMAN; HUMAN EXPERIMENT; MENOPAUSAL SYNDROME; PARTIAL THROMBOPLASTIN TIME; POLYMERIZATION; POSTMENOPAUSE; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTE COUNT;

CASE-CONTROL STUDIES; DYDROGESTERONE; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; FIBRINOGEN; FIBRINOLYSIS; HEMOSTASIS; HUMANS; LONGITUDINAL STUDIES; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PLATELET COUNT; POSTMENOPAUSE; PROTHROMBIN; PROTHROMBIN TIME; RISK FACTORS; THROMBOPHILIA;

EID: 78649659263     PISSN: 15409996     EISSN: None     Source Type: Journal    
DOI: 10.1089/jwh.2010.2040     Document Type: Article

References (23)

1. Farquhar C, Marjoribanks J, Lethaby A, Suckling JA, Lamberts Q. Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2009;2:CD004143.
2. Peruga J, Kopff A, Krzemińska-Pakuła M. Hormone replacement therapy. The cardiologist's point of view. Prze-gla?d Menopauzalny 2007;1:3-7.
3. Sumino H, Ichikawa S, Sawada Y, et al. Effects of hormone replacement therapy on blood coagulation and fibrinolysis in hypertensive and normotensive postmenopausal women. Thromb Res 2005;115:359-366. (Pubitemid 40283478)
4. Miller VM, Jayachandran M, Heit JA, Owen WG. Estrogen therapy and thrombotic risk. Pharmacol Ther 2006;111: 792-807.
5. Norris LA, Brosnan J, Bonnar J, Conard J, Kluft C, Hellgren M. Inhibitors and activation markers of the haemostatic system during hormone therapy: A comparative study of oral estradiol (2mg)=dydrogesterone and estradiol (2mg)=trimegestone. Thromb Haemost 2008;100:253-260.
6. Simomcini T, Mannella P, Genazzani AR. When hormone therapy sneaks under your nose. Menopause 2008;15: 215-216.
7. Kostka B, Para J, Sikora J. A multiparameter test of clot formation and fibrinolysis for in-vitro drug screening. Blood Coagulation Fibrinol 2007;18:611-618.
8. Sandset PM, Hoibraaten E, Eilertsen AL, Dahm A. Mechanism of thromboss related to hormone therapy. Thromb Res 2009;123:70-73.
9. Hellgren M, Conrad J, Norrs L, Kluft C. Cardiovascular risk markers durng treatment with estradiol and trimegestone or dydrogesterone. Maturitas 2009;62:287-293.
10. Barczyński B, Kotarski J. Hormonal therapy and thrombo-embolic disease. Przegla?d Menopauzalny 2008;3:127-131.
11. Junge W, El Samalouti V, Gerlinger C, Schaefers M. Effects of menopausal hormone therapy on hemostatic parameters, blood pressure, and body weight: Open-label comparison of randomized treatment with estradiol plus drospirenone versus estradiol plus norethisterone acetate. Eur J Obstet Gynecol Reprod Biol 2009;147:195-200.
12. Rosendaal FR, Reitsma PH. Genetics of venous thrombosis. J Thromb Haemost 2009;7 (Suppl 1):301-304.
13. Koster T, Rosendaal FR, Reitsma PH, van der Velden PA, Briet E, Vandenbroucke JP. Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms\The Leiden Throm-bophilia Study (LETS). Thromb Haemost 1994;71:719-722.
14. Kostka T, Para J, Kostka B. Correlates of plasma fibrinogen (FG) levels in a random sample of community-dwelling elderly. Arch Gerontol Geriatr 2008;46:211-220.
15. Parastatidis I, Thomson L, Burke A, et al. Fibrinogen beta-chain tyrosine nitration is a prothrombotic risk factor. J Biol Chem 2008;283:33846-33853.
16. Stachowiak G, Pertyński T. Cardiologic safety of menopausal hormone therapies. Przegla?d Menopauzalny 2009;6:1-5.
17. Marx PF. Thrombin-activatable fibrinolysis inhibitor. Curr Med Chem 2004;11:2335-2248.
18. Bouma BN, Marx PF, Mosnier LO, Meijers JC. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarbox-ypeptidase B, procarboxypeptidase R, procarboxypeptidase U). Thromb Res 2001;101:329-354.
19. Bouma BN, Mosnier LO. Thrombin activatable fibrinolysis inhibitor (TAFI) at the interface between coagulation and fibrinolysis. Pathophysiol Haemost Thromb 2003;33: 375-381.
20. Bhasin N, Ariens RA, West RM, Parry DJ, Grant PJ, Scott DJ. Altered fibrin clot structure and function in the healthy first-degree relatives of subjects with intermittent claudication. J Vasc Surg 2008;48:1497-1503.
21. Chu MC, Cushman M, Solomon R, Lobo RA. Metabolic syndrome in postmenopausal women: The influence of oral or transdermal estradiol on inflammation and coagulation markers. Am J Obstet Gynecol 2008;199:526-527.
22. Bonduki CE, Lourenco DM, Motta EL, Soares JM Jr, Haidar MA, Baracat EC. Effect of estrogen-progestin hormonal replacement therapy on blood coagulation and fibrinolysis in postmenopausal women. Clinics (Sao Paulo) 2007;62: 553-560.
23. Quinsey NS, Greedy AL, Bottomley SP, Whisstock JC, Pike RN. Antithrombin: In control of coagulation. Int J Biochem Cell Biol 2004;36:386-389.